Success Metrics

Clinical Success Rate
87.2%

Based on 68 completed trials

Completion Rate
87%(68/78)
Active Trials
12(9%)
Results Posted
29%(20 trials)
Terminated
10(7%)

Phase Distribution

Ph early_phase_1
8
6%
Ph not_applicable
46
34%
Ph phase_3
11
8%
Ph phase_2
38
28%
Ph phase_4
10
7%
Ph phase_1
22
16%

Phase Distribution

30

Early Stage

38

Mid Stage

21

Late Stage

Phase Distribution135 total trials
Early Phase 1First-in-human
8(5.9%)
Phase 1Safety & dosage
22(16.3%)
Phase 2Efficacy & side effects
38(28.1%)
Phase 3Large-scale testing
11(8.1%)
Phase 4Post-market surveillance
10(7.4%)
N/ANon-phased studies
46(34.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

74.7%

68 of 91 finished

Non-Completion Rate

25.3%

23 ended early

Currently Active

12

trials recruiting

Total Trials

135

all time

Status Distribution
Active(18)
Completed(68)
Terminated(23)
Other(26)

Detailed Status

Completed68
unknown26
Withdrawn13
Terminated10
Recruiting8
Not yet recruiting5

Development Timeline

Analytics

Development Status

Total Trials
135
Active
12
Success Rate
87.2%
Most Advanced
Phase 4

Trials by Phase

Early Phase 18 (5.9%)
Phase 122 (16.3%)
Phase 238 (28.1%)
Phase 311 (8.1%)
Phase 410 (7.4%)
N/A46 (34.1%)

Trials by Status

unknown2619%
completed6850%
not_yet_recruiting54%
withdrawn1310%
active_not_recruiting43%
recruiting86%
terminated107%
enrolling_by_invitation11%

Recent Activity

Clinical Trials (135)

Showing 20 of 135 trialsScroll for more
NCT07251985Phase 2

Cognitive Effects of Bioavailable Curcumin

Withdrawn
NCT02782949Phase 2

Curcumin in Preventing Gastric Cancer in Patients With Chronic Atrophic Gastritis or Gastric Intestinal Metaplasia

Active Not Recruiting
NCT07523256Not Applicable

Effect of Curcumin Add-On Therapy on Quality of Life and IL-1β Levels in Patients With Schizophrenia

Completed
NCT02064673Phase 3

Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy

Recruiting
NCT07436130Not Applicable

Curcumin in Critically Ill Patients With Sepsis

Not Yet Recruiting
NCT02724202Early Phase 1

Curcumin in Combination With 5FU for Colon Cancer

Terminated
NCT02554344Early Phase 1

Effect of Curcumin in Treatment of Squamous Cervical Intraepithelial Neoplasias (CINs)

Withdrawn
NCT07379177Not Applicable

Evaluation of the Pharmacokinetics of Curcumin Capsules in Healthy Human

Not Yet Recruiting
NCT06359665Phase 1

Oral Curcumin for the Treatment of Pain of Thumb Base Joint (CMC) Arthritis

Enrolling By Invitation
NCT05377242Not Applicable

Curcumin, Resveratrol, and Stinging Nettle as Treatments for GWI

Active Not Recruiting
NCT06055894Not Applicable

A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)

Recruiting
NCT03865992Not Applicable

Curcumin in Reducing Joint Pain in Breast Cancer Survivors With Aromatase Inhibitor-Induced Joint Disease

Active Not Recruiting
NCT03935958Not Applicable

Curcumin in Kidney Transplant Recipients

Active Not Recruiting
NCT05062486Phase 2

A Study to Evaluate the Safety and Efficacy of RQC for AMD

Completed
NCT03769766Phase 3

Trial of Curcumin to Prevent Progression of Low-risk Prostate Cancer Under Active Surveillance

Recruiting
NCT06458465Not Applicable

Impact of Curcumin and Pentoxiphylline on Chronic Kidney Disease Patients

Completed
NCT06080841Not Applicable

Curcumin Supplementation in Cervical Cancer

Recruiting
NCT06984640Not Applicable

Curcumin Supplementation for the Improvement of Diabetes-related Outcomes

Completed
NCT02598726Phase 1

Curcumin and Piperine in Reducing Inflammation for Ureteral Stent-Induced Symptoms in Patients With Cancer

Completed
NCT05947513Not Applicable

Concomitant Curcumin Palliative Radiotherapy in Advanced Cervical Cancer Trial

Recruiting

Drug Details

Intervention Type
DIETARY SUPPLEMENT
Total Trials
135